CORE C. IMMUNE ASSAY, FLOW CYTOMETRY AND GENE PROFILING This Core will support the Projects of this program project by providing flow cytometry and gene expression profiling services and by performing in vitro functional assays to monitor the immune status of subjects participating in clinical trials. For the clinical trial described in Project 1, the Core will be used to document the development of T cell tolerance to donor or host alloantigens, and assess the ability of the reconstituted patients to mount an immune response to newly introduced as well as recall antigens. For all four Projects the Core will provide flow cytometry based cellular phenotype analysis including the determination of adequate host T cell depletion and the monitoring of T cell recovery following hematopoiefic progenitor cell transplantation for the patients in the clinical trials (Project 1) and for cell phenotype analysis and purification (Projects 2-4). The Core will also provide gene expression profiling to idenfify genes associated with clinical immune tolerance in transplant recipients (Project 1), identify specific cell types expressing these genes (Projects 1 and 4) or identify genes that are differentially expressed in functional subsets of dendritic cells (Project 4).

Public Health Relevance

Some patients tolerate transplanted organs without the need for dangerous immunosuppressive drugs. The goal of this Core is to support the effort in all of the Projects to identify the cells, genes and substances required for this tolerant state. If we are successful, future organ transplant recipients may no longer need to be treated with such toxic drugs.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL075462-10
Application #
8676864
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
10
Fiscal Year
2014
Total Cost
$223,248
Indirect Cost
$83,717
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Müller, Antonia M S; Poyser, Jessica; Küpper, Natascha J et al. (2014) Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood 123:2882-92
Alonso, Michael N; Gregorio, Josh G; Davidson, Matthew G et al. (2014) Depletion of inflammatory dendritic cells with anti-CD209 conjugated to saporin toxin. Immunol Res 58:374-7
Strober, Samuel (2014) Path to clinical transplantation tolerance and prevention of graft-versus-host disease. Immunol Res 58:240-8
Medeiros, B C; Tian, L; Robenson, S et al. (2014) European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Blood Cancer J 4:e216
Sega, Emanuela I; Leveson-Gower, Dennis B; Florek, Mareike et al. (2014) Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One 9:e86551
Hongo, D; Tang, X; Baker, J et al. (2014) Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant 14:2467-77
Schneidawind, Dominik; Pierini, Antonio; Negrin, Robert S (2013) Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood 122:3116-21
Colonna, Lucrezia; Florek, Mareike; Leveson-Gower, Dennis B et al. (2013) IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation. Biol Blood Marrow Transplant 19:1557-65
Davidson, Matthew G; Alonso, Michael N; Kenkel, Justin A et al. (2013) In vivo T cell activation induces the formation of CD209(+) PDL-2(+) dendritic cells. PLoS One 8:e76258
Kohrt, Holbrook E; Tian, Lu; Li, Li et al. (2013) Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clin Immunol 148:124-35

Showing the most recent 10 out of 35 publications